More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg.
Cell and Gene therapy experts from the international consortium ‘CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment’ (CAR T-REX) gathered on the 28 and 29 May for a General Assembly at CiQUS, Universidade de Santiago de Compostela.
Leibniz scientists significantly involved in national strategy for gene and cell-based therapies.
Luca Gattinoni and Matthias Edinger from the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) have received a 2.6 million euro grant from the German Cancer Aid. The funding will support an innovative clinical study using stem-like CAR T cells to treat patients with advanced lymphomas.
The International LIT Symposium takes place June 26th – 27th, 2024 in Regensburg, Germany.
Dr. Jeremy Baldwin, Postdoctoral Scientist in the Functional Immune Cell Modulation Division of the LIT, received an Add-on Fellowships for Interdisciplinary Life Science of 12.500€ by the Joachim Herz Foundation for his research project on metabolically reprogramming CD8+ T cells for cancer immunotherapy applications.
Peter Aumer and Katrin Staffler, members of the German Bundestag, visited the LIT on January 24, 2024.
The Scientific Director of the Leibniz Institute for Immunotherapy (LIT), Prof. Philipp Beckhove, visited the German Bundestag. The attending deputies were impressed by the excellent research conducted at LIT. Subsequently, possibilities were discussed to enhance the international competitiveness of biomedical research in Germany.
